A novel monophosphite ligand having a tert-butyloxycarbonyl group is useful as a ligand in hydroformylation of an olefin.

Patent
   9221850
Priority
May 20 2014
Filed
May 18 2015
Issued
Dec 29 2015
Expiry
May 18 2035
Assg.orig
Entity
Large
4
5
EXPIRED<2yrs
1. A ligand having structure I or II:
##STR00041##
wherein
R1, R2, R3, R4, R5, R6, R7, R8 are each independently selected from the group consisting of: —H, —(C1-C12)-alkyl, —O—(C1-C12)-alkyl, —O—(C6-C20)-aryl, —(C6-C20)-aryl, halogen, COO—(C1-C12)-alkyl, CONH—(C1-C12)-alkyl, —(C6-C20)-aryl-CON[(C1-C12)-alkyl]2, —CO—(C1-C12)-alkyl, —CO—(C6-C20)-aryl, —COOH, —OH, —SO3H, —SO3Na, —NO2, —CN, —NH2, and —N[(C1-C12)-alkyl]2;
X and Y are each independently selected from the group consisting of
—(C1-C12)-alkyl, —(C6-C20)-aryl, —(C6-C20)-aryl-(C1-C12)-alkyl, —(C6-C20)-aryl-O—(C1-C12)-alkyl, —(C1-C12)-alkyl-(C6-C20)-aryl, —(C6-C20)-aryl-COO—(C1-C12)-alkyl, —(C6-C20)-aryl-CONH—(C1-C12)-alkyl, —(C6-C20)-aryl-CON[(C1-C12)-alkyl]2, —(C4-C20)-heteroaryl, —(C4-C20)-heteroaryl-(C1-C12)-alkyl, and —(C5-C8)-cycloalkyl-(C4-C20)-aryl-CO—(C6-C20)-aryl,
Z is selected from the group consisting of
—(C1-C12)-alkyl-, —(C6-C20)-aryl-, —(C6-C20)-aryl-(C1-C12)-alkyl-, —(C1-C12)-alkyl-(C6-C20)-aryl-, —(C4-C20)-heteroaryl-, —(C6-C20)-aryl-CO—(C6-C20)-aryl-, and —(C6-C20)-aryl-(C6-C20)-aryl-;
wherein the alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl groups mentioned are optionally substituted.
2. The ligand according to claim 1, wherein X and Y are each independently selected from the group consisting of
—(C1-C12)-alkyl, —(C6-C20)-aryl, —(C6-C20)-aryl-(C1-C12)-alkyl, —(C6-C20)-aryl-O—(C1-C12)-alkyl, —(C6-C20)-aryl-COO—(C1-C12)-alkyl, —(C6-C20)-aryl-CONH—(C1-C12)-alkyl, —(C6-C20)-aryl-CON[(C1-C12)-alkyl]2, —(C4-C20)-heteroaryl, and —(C4-C20)-heteroaryl-(C1-C12)-alkyl.
3. The ligand according to claim 1, wherein X and Y are each independently selected from the group consisting of
—(C1-C12)-alkyl, —(C6-C20)-aryl, —(C6-C20)-aryl-(C1-C12)-alkyl, —(C6-C20)-aryl-O—(C1-C12)-alkyl, and —(C6-C20)-aryl-COO—(C1-C12)-alkyl.
4. The ligand according to claim 1, wherein Z is selected from the group consisting of
—(C1-C12)-alkyl-, —(C6-C20)-aryl-, —(C6-C20)-aryl-(C1-C12)-alkyl-, —(C6-C20)-aryl-CO—(C6-C20)-aryl-, —(C1-C12)-alkyl-(C6-C20)-aryl-, and —(C6-C20)-aryl-(C6-C20)-aryl-.
5. The ligand according to claim 1, wherein R1, R2, R3, R4, R5, R6, R7, R8 are each independently selected from the group consisting of —H, —(C1-C12)-alkyl, —O—(C1-C12)-alkyl, —O—(C6-C20)-aryl, —(C6-C20)-aryl, —COO—(C1-C12)-alkyl, —CONH—(C1-C12)-alkyl, —(C6-C20)-aryl-CON[(C1-C12)-alkyl]2, —CO—(C1-C12)-alkyl, —CO—(C6-C20)-aryl, —COOH, —OH, —NH2, and —N[(C1-C12)-alkyl]2.
6. The ligand according to claim 1, wherein X and Y are the same radicals.
7. The ligand according to claim 1, wherein R3 and R6 are each —O—(C1-C12)-alkyl.
8. The ligand according to claim 1, wherein R3 and R6 are each —OMe.
9. The ligand according to claim 1, wherein R1 and R8 are each —(C1-C12)-alkyl.
10. The ligand according to claim 1, wherein R and R8 are each tert-butyl.
11. The ligand according to claim 1, having the general structure III:
##STR00042##
wherein R9, R10, R11, R12, R13, R14, R15, R16 are each independently selected from the group consisting of
—H, —(C1-C12)-alkyl, —O—(C1-C12)-alkyl, —O—(C6-C20)-aryl, —(C6-C20)-aryl, -halogen, —COO—(C1-C12)-alkyl, —CONH—(C1-C12)-alkyl, —(C6-C20)-aryl-CON[(C1-C12)-alkyl]2, —CO—(C1-C12)-alkyl, —CO—(C6-C20)-aryl, —COOH, —OH, —SO3H, —SO3Na, —NO2, —CN, —NH2, and —N[(C1-C12)-alkyl]2.
12. The ligand according to claim 1, having the general structure IV:
##STR00043##
wherein R9, R10, R1, R12, R13, R14, R15, R16 are each independently selected from the group consisting of
—H, —(C1-C12)-alkyl, —O—(C1-C12)-alkyl, —O—(C6-C20)-aryl, —(C6-C20)-aryl, -halogen, —COO—(C1-C12)-alkyl, —CONH—(C1-C12)-alkyl, —(C6-C20)-aryl-CON[(C1-C12)-alkyl]2, —CO—(C1-C12)-alkyl, —CO—(C6-C20)-aryl, —COOH, —OH, —SO3H, —SO3Na, —NO2, —CN, —NH2, and —N[(C1-C12)-alkyl]2.
13. The ligand according to claim 1, which has the structure I.
14. The ligand according to claim 1, which has the structure II.
15. The ligand according to claim 1, which has a structure selected from the group consisting of the following structures 1 to 70:
##STR00044## ##STR00045## ##STR00046## ##STR00047## ##STR00048## ##STR00049## ##STR00050## ##STR00051## ##STR00052## ##STR00053## ##STR00054## ##STR00055## ##STR00056## ##STR00057## ##STR00058## ##STR00059## ##STR00060## ##STR00061##
16. A complex, comprising:
the ligand according to claim 1, and
a metal atom selected from the group consisting of Rh, Ru, Co, and Ir.
17. A process for the hydroformylation of an olefin, comprising:
a) initially charging an olefin,
b) adding
the complex according to claim 13, to obtain a reaction mixture,
c) feeding H2 and CO into the reaction mixture,
d) heating the reaction mixture, to obtain conversion of the olefin to an aldehyde.
18. A process for the hydroformylation of an olefin, comprising:
a) initially charging an olefin,
b) adding a ligand according to claim 1 and a compound including a metal atom selected from the group consisting of Rh, Ru, Co, and Ir, to obtain a reaction mixture,
c) feeding H2 and CO into the reaction mixture,
d) heating the reaction mixture, to obtain conversion of the olefin to an aldehyde.

The invention relates to a novel monophosphite ligand having a tert-butyloxycarbonyl group), to use thereof as ligand in hydroformylation and to the hydroformylation process.

The reactions between olefin compounds, carbon monoxide and hydrogen in the presence of a catalyst to give the aldehydes comprising one additional carbon atom are known as hydroformylation or oxo synthesis. The catalysts used in these reactions are frequently compounds of the transition metals of group VIII of the Periodic Table of the Elements. Known ligands are, for example, compounds from the classes of the phosphines, phosphites and phosphonites, each with trivalent phosphorus PIII. A good overview of the state of the hydroformylation of olefins can be found in B. CORNILS, W. A. HERRMANN, “Applied Homogeneous Catalysis with Organometallic Compounds”, vol. 1 & 2, VCH, Weinheim, N.Y., 1996 or R. Franke, D. Selent, A. Bönier, “Applied Hydroformylation”, Chem. Rev., 2012, DOI:10.1021/cr3001803.

Every catalytically active composition has its specific benefits. According to the feedstock and target product, therefore, different catalytically active compositions are used.

The disadvantage of bi- and polydentate phosphine ligands is a relatively high level of complexity necessary for preparation thereof. It is therefore often unfeasible to use such systems in industrial operations. An additional factor is comparatively low activity, which has to be compensated for by chemical engineering, through high residence times. This in turn leads to unwanted side reactions of the products.

In Angew. Chem. Int. Ed. 2000, 39, No. 9, p. 1639-1641, Börner et al. describe ligands having one P—C bond and two P—O bonds; these are thus phosphonites. The phosphonites described therein, when used in hydroformylation, have n/iso selectivities (n/iso=the ratio of linear aldehyde (=n) to branched (=iso) aldehyde)) of 0.61 to 1.57.

The phosphonite ligands described in DE 199 54 721 have a good n/iso selectivity. However, in-house studies have shown that the compound II-c (in DE 199 54 721; page 6) has a tendency to photochemically induced breakdown, and should therefore not be used on the industrial scale.

One disadvantage of the ligands having a phosphonite structure is that their preparation is very complex. However, the possibility of a favourable and simple synthesis is crucial for the use of ligands in an industrial scale process.

Ease of availability and the associated good possibility of industrial scale use is an important criterion, since the preparation complexity and the associated production costs for the ligand may only be so high that the viability of the overall process in which the ligand is to be used at a later stage is still assured.

Rhodium-monophosphite complexes in catalytically active compositions are suitable for the hydroformylation of branched olefins having internal double bonds.

Since the 1970s, there have been descriptions of the use of “bulky phosphites” in hydroformylation (see, inter alia, van Leeuwen et al., Journal of Catalysis, 2013, 298, 198-205). These feature good activity, but the n/i selectivity for terminally hydroformylated compounds is in need of improvement.

EP 0 155 508 discloses the use of bisarylene-substituted monophosphites in the rhodium-catalysed hydroformylation of sterically hindered olefins, e.g. isobutene. However, rhodium concentrations used here are sometimes very high (one being 250 ppm), which is unacceptable for an industrial scale process in view of the current cost of rhodium and has to be improved.

For hydroformylation reactions, tris(2,4-di-tert-butylphenyl)phosphite (TDTBPP) is currently one of the best-performing monophosphite ligands commercially available, and is available under the Alkanox 240 trade name (see also R. Franke, D. Selent, A. Börner, “Applied Hydroformylation”, Chem. Rev., 2012, 112, p. 5681, chapter 3.4.2).

The technical object that formed the basis of the present invention is that of providing a novel monophosphite ligand which does not have the above-detailed disadvantages from the related art in the hydroformylation of unsaturated compounds.

Firstly, the preparation complexity should be lower than for the above-described phosphonite ligands; secondly, a good n selectivity should be achieved in relation to the hydroformylation.

More particularly, the novel monophosphite ligands should also be suitable for hydroformylation of industrial olefin mixtures containing mainly branched olefins having internal double bonds. In the hydroformylation, at the same time, a high proportion of desired terminally hydroformylated products should be obtained.

The above and other objects are achieved by a ligand having structure I or II:

##STR00001##

wherein

R1, R2, R3, R4, R5, R6, R7, R8 are each independently selected from the group consisting of: —H, —(C1-C12)-alkyl, —O—(C1-C12)-alkyl, —O—(C6-C20)-aryl, —(C6-C20)-aryl, halogen, COO—(C1-C12)-alkyl, CONH—(C1-C12)-alkyl, —(C6-C20)-aryl-CON[(C1-C12)-alkyl]2, —CO—(C1-C12)-alkyl, —CO—(C6-C20)-aryl, —COOH, —OH, —SO3H, —SO3Na, —NO2, —CN, —NH2, and —N[(C1-C12)-alkyl]2;

X and Y are each independently selected from the group consisting of

Z is selected from the group consisting of

—(C1-C12)-alkyl-, —(C6-C20)-aryl-, —(C6-C20)-aryl-(C1-C12)-alkyl-, —(C1-C12)-alkyl-(C6-C20)-aryl-, —(C4-C20)-heteroaryl-, —(C6-C20)-aryl-CO—(C6-C20)-aryl-, and —(C6-C20)-aryl-(C6-C20)-aryl-;

wherein the alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl groups mentioned are optionally substituted.

In another embodiment, the present invention relates to a complex, comprising:

the above ligand, and

a metal atom selected from the group consisting of Rh, Ru, Co, and Ir.

In another embodiment, the present invention relates to a process for the hydroformylation of an olefin, comprising:

a) initially charging an olefin,

b) adding

the above complex, to obtain a reaction mixture,

c) feeding H2 and CO into the reaction mixture,

d) heating the reaction mixture, to obtain conversion of the olefin to an aldehyde.

In another embodiment, the present invention relates to a process for the hydroformylation of an olefin, comprising:

a) initially charging an olefin,

b) adding the above ligand and a compound including a metal atom selected from the group consisting of Rh, Ru, Co, and Ir, to obtain a reaction mixture,

c) feeding H2 and CO into the reaction mixture,

d) heating the reaction mixture, to obtain conversion of the olefin to an aldehyde.

The present invention relates to a ligand having one of the two general structures I and II:

##STR00002##
wherein

R1, R2, R3, R4, R5, R6, R7, R8 are each independently selected from: —H, —(C1-C12)-alkyl, —O—(C1-C12)-alkyl, —O—(C6-C20)-aryl, —(C6-C20)-aryl, halogen (such as Cl, F, Br, I), COO—(C1-C12)-alkyl, CONH—(C1-C12)-alkyl, —(C6-C20)-aryl-CON[(C1-C12)-alkyl]2, —CO—(C1-C12)-alkyl, —CO—(C6-C20)-aryl, —COOH, —OH, —SO3H, —SO3Na, —NO2, —CN, —NH2, —N[(C1-C12)-alkyl]2;

X and Y are each independently selected from:

—(C1-C12)-alkyl, —(C6-C20)-aryl, —(C6-C20)-aryl-(C1-C12)-alkyl, —(C6-C20)-aryl-O—(C1-C12)-alkyl, —(C1-C12)-alkyl-(C6-C20)-aryl, —(C6-C20)-aryl-COO—(C1-C12)-alkyl, —(C6-C20)-aryl-CONH—(C1-C12)-alkyl, —(C6-C20)-aryl-CON[(C1-C12)-alkyl]2, —(C4-C20)-heteroaryl, —(C4-C20)-heteroaryl-(C1-C12)-alkyl, —(C5-C8)-cycloalkyl, —(C6-C20)-aryl-CO—(C6-C20)-aryl,

Z is selected from:

—(C1-C12)-alkyl-, —(C6-C20)-aryl-, —(C6-C20)-aryl-(C1-C12)-alkyl-, —(C1-C12)-alkyl-(C6-C20)-aryl-, —(C4-C20)-heteroaryl-, —(C6-C20)-aryl-CO—(C6-C20)-aryl-, —(C6-C20)-aryl-(C6-C20)-aryl-;

where the alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl groups mentioned may be substituted.

(C1-C12)-Alkyl and O—(C1-C12)-alkyl may each be unsubstituted or substituted by one or more identical or different radicals selected from (C3-C12)-cycloalkyl, (C3-C12)-heterocycloalkyl, (C6-C20)-aryl, fluorine, chlorine, cyano, formyl, acyl and alkoxycarbonyl.

(C3-C12)-Cycloalkyl and (C3-C12)-heterocycloalkyl may each be unsubstituted or substituted by one or more identical or different radicals selected from (C1-C12)-alkyl, (C1-C12)-alkoxy, (C3-C12)-cycloalkyl, (C3-C12)-heterocycloalkyl, (C6-C20)-aryl, fluorine, chlorine, cyano, formyl, acyl and alkoxycarbonyl.

(C6-C20)-Aryl and —(C6-C20)-aryl-(C6-C20)-aryl- may each be unsubstituted or substituted by one or more identical or different radicals selected from:

—H, —(C1-C12)-alkyl, —O—(C1-C12)-alkyl, —O—(C6-C20)-aryl, —(C6-C20)-aryl, -halogen (such as Cl, F, Br, I), —COO—(C1-C12)-alkyl, —CONH—(C1-C12)-alkyl, —(C6-C20)-aryl-CON[(C1-C12)-alkyl]2, —CO—(C1-C12)-alkyl, —CO—(C6-C20)-aryl, —COOH, —OH, —SO3H, —SO3Na, —NO2, —CN, —NH2, —N[(C1-C12)-alkyl]2.

In the context of the invention, the expression —(C1-C12)-alkyl encompasses straight-chain and branched alkyl groups. Preferably, these groups are unsubstituted straight-chain or branched —(C1-C8)-alkyl groups and most preferably —(C1-C6)-alkyl groups. Examples of (C1-C12)-alkyl groups are especially methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 2-methylbutyl, 3-methylbutyl, 1,2-dimethylpropyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, 2-hexyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethylbutyl, 1-ethyl-2-methylpropyl, n-heptyl, 2-heptyl, 3-heptyl, 2-ethylpentyl, 1-propylbutyl, n-octyl, 2-ethylhexyl, 2-propylheptyl, nonyl, decyl.

The elucidations relating to the expression —(C1-C12)-alkyl also apply to the alkyl groups in —O—(C1-C12)-alkyl, i.e. in —(C1-C12)-alkoxy. Preferably, these groups are unsubstituted straight-chain or branched —(C1-C6)-alkoxy groups.

Substituted —(C1-C12)-alkyl groups and substituted —(C1-C12)-alkoxy groups may have one or more substituents, depending on their chain length. The substituents are preferably each independently selected from —(C3-C12)-cycloalkyl, —(C3-C12)-heterocycloalkyl, —(C6-C20)-aryl, fluorine, chlorine, cyano, formyl, acyl or alkoxycarbonyl.

The expression “—(C3-C12)-heterocycloalkyl groups”, in the context of the present invention, encompasses nonaromatic saturated or partly unsaturated cycloaliphatic groups having 3 to 12, especially 5 to 12, carbon atoms. The —(C3-C12)-heterocycloalkyl groups have preferably 3 to 8, more preferably 5 or 6, ring atoms. In the heterocycloalkyl groups, as opposed to the cycloalkyl groups, 1, 2, 3 or 4 of the ring carbon atoms are replaced by heteroatoms or heteroatom-containing groups. The heteroatoms or the heteroatom-containing groups are preferably selected from —O—, —S—, —N—, —N(═O)—, —C(═O)— and —S(═O)—. Examples of —(C3-C12)-heterocycloalkyl groups are tetrahydrothiophenyl, tetrahydrofuryl, tetrahydropyranyl and dioxanyl.

Substituted —(C3-C12)-cycloalkyl groups and substituted —(C3-C12)-heterocycloalkyl groups may have one or more (e.g. 1, 2, 3, 4 or 5) further substituents, depending on their ring size. These substituents are preferably each independently selected from —(C1-C12)-alkyl, —(C1-C12)-alkoxy, —(C3-C12)-cycloalkyl, —(C3-C12)-heterocycloalkyl, —(C6-C20)-aryl, fluorine, chlorine, cyano, formyl, acyl or alkoxycarbonyl. Substituted —(C3-C12)-cycloalkyl groups preferably bear one or more —(C1-C6)-alkyl groups. Substituted —(C3-C12)-heterocycloalkyl groups preferably bear one or more —(C1-C6)-alkyl groups.

In the context of the present invention, the expression —(C6-C20)-aryl and —(C6-C20)-aryl-(C6-C20)-aryl- encompasses mono- or polycyclic aromatic hydrocarbyl radicals. These have 6 to 20 ring atoms, more preferably 6 to 14 ring atoms, especially 6 to 10 ring atoms. Aryl is preferably —(C6-C10)-aryl and —(C6-C10)-aryl-(C6-C10)-aryl-. Aryl is especially phenyl, naphthyl, indenyl, fluorenyl, anthracenyl, phenanthrenyl, naphthacenyl, chrysenyl, pyrenyl, coronenyl. More particularly, aryl is phenyl, naphthyl and anthracenyl.

Substituted —(C6-C20)-aryl groups and —(C6-C20)-aryl-(C6-C20)-aryl groups may have one or more (e.g. 1, 2, 3, 4 or 5) substituents, depending on their ring size. These substituents are preferably each independently selected from —H, —(C1-C12)-alkyl, —O—(C1-C12)-alkyl, —O—(C6-C20)-aryl, —(C6-C20)-aryl, -halogen (such as Cl, F, Br, I), —COO—(C1-C12)-alkyl, —CONH—(C1-C12)-alkyl, —(C6-C20)-aryl-CON[(C1-C12)-alkyl]2, —CO—(C1-C12)-alkyl, —CO—(C6-C20)-aryl, —COOH, —OH, —SO3H, —SO3Na, —NO2, —CN, —NH2, —N[(C1-C12)-alkyl]2.

Substituted —(C6-C20)-aryl groups and —(C6-C20)-aryl-(C6-C20)-aryl groups are preferably substituted —(C6-C10)-aryl groups and —(C6-C10)-aryl-(C6-C10)-aryl groups, especially substituted phenyl or substituted naphthyl or substituted anthracenyl. Substituted —(C6-C20)-aryl groups preferably bear one or more, for example 1, 2, 3, 4 or 5, substituents selected from —(C1-C12)-alkyl groups, —(C1-C12)-alkoxy groups.

Any ranges mentioned herein include all values and subvalues of between the lower and upper limits of the range.

In one embodiment, X and Y are each independently selected from:

—(C1-C12)-alkyl, —(C6-C20)-aryl, —(C6-C20)-aryl-(C1-C12)-alkyl, —(C6-C20)-aryl-O—(C1-C12)-alkyl, —(C6-C20)-aryl-COO—(C1-C12)-alkyl, —(C6-C20)-aryl-CONH—(C1-C12)-alkyl, —(C6-C20)-aryl-CON[(C1-C12)-alkyl]2, —(C4-C20)-heteroaryl, —(C4-C20)-heteroaryl-(C1-C12)-alkyl.

In one embodiment, X and Y are each independently selected from:

—(C1-C12)-alkyl, —(C6-C20)-aryl, —(C6-C20)-aryl-(C1-C12)-alkyl, —(C6-C20)-aryl-O—(C1-C12)-alkyl, —(C6-C20)-aryl-COO—(C1-C12)-alkyl.

In one embodiment, X and Y are each independently selected from:

—(C1-C12)-alkyl, —(C6-C20)-aryl, —(C6-C20)-aryl-(C1-C12)-alkyl, —(C6-C20)-aryl-O—(C1-C12)-alkyl.

In one embodiment, Z is selected from:

—(C1-C12)-alkyl-, —(C6-C20)-aryl-, —(C6-C20)-aryl-(C1-C12)-alkyl-, —(C6-C20)-aryl-CO—(C6-C20)-aryl-, —(C1-C12)-alkyl-(C6-C20)-aryl-, —(C6-C20)-aryl-(C6-C20)-aryl-.

In one embodiment, Z is:

##STR00003##

In one embodiment, Z is:

—(C6-C20)-aryl-(C6-C20)-aryl-.

In one embodiment, R1, R2, R3, R4, R5, R6, R7, R8 are each independently selected from:

—H, —(C1-C12)-alkyl, —O—(C1-C12)-alkyl, —O—(C6-C20)-aryl, —(C6-C20)-aryl, —COO—(C1-C12)-alkyl, —CONH—(C1-C12)-alkyl, —(C6-C20)-aryl-CON[(C1-C12)-alkyl]2, —CO—(C1-C12)-alkyl, —CO—(C6-C20)-aryl, —COOH, —OH, —NH2, —N[(C1-C12)-alkyl]2.

In one embodiment, R1, R2, R3, R4, R5, R6, R7, R8 are each independently selected from:

—H, —(C1-C12)-alkyl, —O—(C1-C12)-alkyl, —O—(C6-C20)-aryl, —(C6-C20)-aryl, —COO—(C1-C12)-alkyl, —N[(C1-C12)-alkyl]2.

In one embodiment, R1, R2, R3, R4, R5, R6, R7, R8 are each independently selected from:

—H, —(C1-C12)-alkyl, —O—(C1-C12)-alkyl, —(C6-C20)-aryl.

In one embodiment, X and Y are the same radicals.

In one embodiment, R3 and R6 are each —O—(C1-C12)-alkyl.

In one embodiment, R3 and R6 are each —OMe.

In one embodiment, R1 and R8 are each —(C1-C12)-alkyl.

In one embodiment, R1 and R8 are each tert-butyl.

In one embodiment, R1, R3, R6 and R8 are each —(C1-C12)-alkyl.

In one embodiment, R1, R3, R6 and R8 are each methyl.

In one embodiment, R1, R3, R6 and R8 are each tert-butyl.

In one embodiment, R1, R2, R3, R4, R5, R6, R7 and R8 are each —H.

In one embodiment, the ligand has the general structure III:

##STR00004##
where R9, R10, R11, R12, R13, R14, R15, R16 are each independently selected from:

—H, —(C1-C12)-alkyl, —O—(C1-C12)-alkyl, —O—(C6-C20)-aryl, —(C6-C20)-aryl, -halogen (such as Cl, F, Br, I), —COO—(C1-C12)-alkyl, —CONH—(C1-C12)-alkyl, —(C6-C20)-aryl-CON[(C1-C12)-alkyl]2, —CO—(C1-C12)-alkyl, —CO—(C6-C20)-aryl, —COOH, —OH, —SO3H, —SO3Na, —NO2, —CN, —NH2, —N[(C1-C12)-alkyl]2.

In one embodiment, R9, R10, R11, R12, R13, R14, R15, R16 are each independently selected from:

—H, —(C1-C12)-alkyl, —O—(C1-C12)-alkyl, —O—(C6-C20)-aryl, —(C6-C20)-aryl, —COO—(C1-C12)-alkyl, —CONH—(C1-C12)-alkyl, —(C6-C20)-aryl-CON[(C1-C12)-alkyl]2, —CO—(C1-C12)-alkyl, —CO—(C6-C20)-aryl, —COOH, —OH, —NH2, —N[(C1-C12)-alkyl]2.

In one embodiment, R9, R10, R11, R12, R13, R14, R15, R16 are each independently selected from:

—H, —(C1-C12)-alkyl, —O—(C1-C12)-alkyl, —O—(C6-C20)-aryl, —(C6-C20)-aryl, —COO—(C1-C12)-alkyl, —N[(C1-C12)-alkyl]2.

In one embodiment, R9, R10, R11, R12, R13, R14, R15, R16 are each independently selected from:

—H, —(C1-C12)-alkyl, —O—(C1-C12)-alkyl, —(C6-C20)-aryl,

where alkyl comprises 1-12 carbon atoms, preferably 1-10 carbon atoms, for example primary, secondary or tertiary alkyl groups such as methyl, ethyl, n-propyl, isopropyl, butyl, sec-butyl, t-butyl, t-butylethyl, t-butylpropyl, n-hexyl, amyl, sec-amyl, t-amyl, isooctyl, 2-ethylhexyl, decyl, dodecyl and octadecyl groups.

In one embodiment, R11 and R14 are each —O—(C1-C12)-alkyl.

In one embodiment, R11 and R14 are each —OMe.

In one embodiment, R9 and R16 are each —(C1-C12)-alkyl.

In one embodiment, R9 and R16 are each tert-butyl.

In one embodiment, R9, R11, R14 and R16 are each —(C1-C12)-alkyl.

In one embodiment, R9, R11, R14 and R16 are each methyl.

In one embodiment, R9, R11, R14 and R16 are each tert-butyl.

In one embodiment, R9, R10, R11, R12, R13, R14, R15 and R16 are each —H.

In one embodiment, the ligand has the general structure IV:

##STR00005##
where R9, R10, R11, R12, R13, R14, R15, R16 are each independently selected from:

—H, —(C1-C12)-alkyl, —O—(C1-C12)-alkyl, —O—(C6-C20)-aryl, —(C6-C20)-aryl, -halogen (such as Cl, F, Br, I), —COO—(C1-C12)-alkyl, —CONH—(C1-C12)-alkyl, —(C6-C20)-aryl-CON[(C1-C12)-alkyl]2, —CO—(C1-C12)-alkyl, —CO—(C6-C20)-aryl, —COOH, —OH, —SO3H, —SO3Na, —NO2, —CN, —NH2, —N[(C1-C12)-alkyl]2.

In one embodiment, R9, R10, R11, R12, R13, R14, R15, R16 are each independently selected from:

—H, —(C1-C12)-alkyl, —O—(C1-C12)-alkyl, —O—(C6-C20)-aryl, —(C6-C20)-aryl, —COO—(C1-C12)-alkyl, —CONH—(C1-C12)-alkyl, —(C6-C20)-aryl-CON[(C1-C12)-alkyl]2, —CO—(C1-C12)-alkyl, —CO—(C6-C20)-aryl, —COOH, —OH, —NH2, —N[(C1-C12)-alkyl]2.

In one embodiment, R9, R10, R11, R12, R13, R14, R15, R16 are each independently selected from:

—H, —(C1-C12)-alkyl, —O—(C1-C12)-alkyl, —O—(C6-C20)-aryl, —(C6-C20)-aryl, —COO—(C1-C12)-alkyl, —N[(C1-C12)-alkyl]2.

In one embodiment, R9, R10, R11, R12, R13, R14, R15, R16 are each independently selected from:

—H, —(C1-C12)-alkyl, —O—(C1-C12)-alkyl, —(C6-C20)-aryl;

where alkyl comprises 1-18 carbon atoms, preferably 1-10 carbon atoms, for example primary, secondary or tertiary alkyl groups such as methyl, ethyl, n-propyl, isopropyl, butyl, sec-butyl, t-butyl, t-butylethyl, t-butylpropyl, n-hexyl, amyl, sec-amyl, t-amyl, isooctyl, 2-ethylhexyl, decyl, dodecyl and octadecyl groups.

In one embodiment, R11 and R14 are each —O—(C1-C12)-alkyl.

In one embodiment, R11 and R14 are each —OMe.

In one embodiment, R9 and R16 are each —(C1-C12)-alkyl.

In one embodiment, R9 and R16 are each tert-butyl.

In one embodiment, R9, R11, R14 and R16 are each —(C1-C12)-alkyl.

In one embodiment, R9, R11, R14 and R16 are each methyl.

In one embodiment, R9, R11, R14 and R16 are each tert-butyl.

In one embodiment, R9, R10, R11, R12, R13, R14, R15 and R16 are each —H.

As well as the ligands, also claimed is a complex comprising these ligands.

Complex comprising:

In a preferred embodiment, the metal is Rh.

In this regard, see R. Franke, D. Selent, A. Bmrner, “Applied Hydroformylation”, Chem. Rev., 2012, DOI:10.1021/cr3001803; p. 5688, Scheme 12 “General Method for the Preparation of a P-Modified Rh precatalyst” and references cited therein, and also P. W. N. M. van Leeuwen, in Rhodium Catalyzed Hydroformylation, P. W. N. M. van Leeuwen, C. Claver (eds.), Kluwer, Dordrecht, 2000, inter alia p. 48 ff, p. 233 ff. and references cited therein, and also K. D. Wiese and D. Obst in Top. Organomet. Chem. 2006, 18, 1-13; Springer Verlag Berlin Heidelberg 2006 p. 6 ff and references cited therein.

Additionally claimed is the use of the ligand as ligand in a ligand-metal complex for catalysis of a hydroformylation reaction.

Use of an above-described ligand in a ligand-metal complex for catalysis of a hydroformylation reaction.

The process in which the ligand is used as ligand in a ligand-metal complex for conversion of an olefin to an aldehyde is likewise claimed.

Process comprising the process steps of:

a) initially charging an olefin,

b) adding an above-described complex,

or an above-described ligand and a compound including a metal atom selected from: Rh, Ru, Co, Ir,

c) feeding in H2 and CO,

d) heating the reaction mixture, with conversion of the olefin to an aldehyde.

In this process, process steps a) to d) can be effected in any desired sequence.

The reaction is conducted under customary conditions.

Preference is given to a temperature of 80° C. to 160° C. and a pressure of 1 to 300 bar.

Particular preference is given to a temperature of 100° C. to 160° C. and a pressure of 15 to 250 bar.

In a preferred embodiment, the metal is Rh.

The reactants for the hydroformylation in the process of the invention are olefins or mixtures of olefins, especially monoolefins having 2 to 24, preferably 3 to 16 and more preferably 3 to 12 carbon atoms, having terminal or internal C—C double bonds, for example 1-propene, 1-butene, 2-butene, 1- or 2-pentene, 2-methyl-1-butene, 2-methyl-2-butene, 3-methyl-1-butene, 1-, 2- or 3-hexene, the C6 olefin mixture obtained in the dimerization of propene (dipropene), heptenes, 2- or 3-methyl-1-hexenes, octenes, 2-methylheptenes, 3-methylheptenes, 5-methyl-2-heptene, 6-methyl-2-heptene, 2-ethyl-1-hexene, the C8 olefin mixture obtained in the dimerization of butenes (di-n-butene, diisobutene), nonenes, 2- or 3-methyloctenes, the C9 olefin mixture obtained in the trimerization of propene (tripropene), decenes, 2-ethyl-1-octene, dodecenes, the C12 olefin mixture obtained in the tetramerization of propene or the trimerization of butenes (tetrapropene or tributene), tetradecenes, hexadecenes, the C16 olefin mixture obtained in the tetramerization of butenes (tetrabutene), and olefin mixtures prepared by cooligomerization of olefins having different numbers of carbon atoms (preferably 2 to 4).

The process according to the invention using the ligands according to the invention can be used to hydroformylate α-olefins, terminally branched, internal and internally branched olefins. What is remarkable is the high yield of terminally hydroformylated olefin, even when only a small proportion of olefins having a terminal double bond was present in the reactant.

The invention is to be illustrated in detail hereinafter by working examples.

Having generally described this invention, a further understanding can be obtained by reference to certain specific examples which are provided herein for purposes of illustration only, and are not intended to be limiting unless otherwise specified.

The following seventy structures (1 to 70) show possible working examples of the ligand:

##STR00006## ##STR00007## ##STR00008## ##STR00009## ##STR00010## ##STR00011## ##STR00012## ##STR00013## ##STR00014## ##STR00015## ##STR00016## ##STR00017## ##STR00018## ##STR00019## ##STR00020## ##STR00021## ##STR00022## ##STR00023##
General Operating Procedures

All the preparations which follow were carried out under protective gas using standard Schlenk techniques. The solvents were dried over suitable desiccants before use (Purification of Laboratory Chemicals, W. L. F. Armarego, Christina Chai, Butterworth Heinemann (Elsevier), 6th edition, Oxford 2009).

All preparative operations were effected in baked-out vessels. The products were characterized by means of NMR spectroscopy. Chemical shifts (δ) are reported in ppm. The 31P NMR signals were referenced according to: SR31P=SR1H*(BF31P/BF1H)=SR1H*0.4048. (Robin K. Harris, Edwin D. Becker, Sonia M. Cabral de Menezes, Robin Goodfellow, and Pierre Granger, Pure Appl. Chem., 2001, 73, 1795-1818; Robin K. Harris, Edwin D. Becker, Sonia M. Cabral de Menezes, Pierre Granger, Roy E. Hoffman and Kurt W. Zilm, Pure Appl. Chem., 2008, 80, 59-84).

Nuclear resonance spectra were recorded by means of a Bruker Avance 300 or Bruker Avance 400; gas chromatography analysis was effected using an Agilent GC 7890A.

The ligands according to the invention can be prepared here in various ways. Three possible ways are shown in the schemes which follow (A to C).

The reaction routes shown are merely illustrative and are shown in highly simplified form. Thus, if required, base can be used additionally in all the steps. In addition, the bases specified in the individual synthesis stages may be replaced by other commercially available bases known to those skilled in the art.

##STR00024## ##STR00025## ##STR00026##

##STR00027## ##STR00028##

In a 2 l Schlenk flask, 400 mmol (143.8 g) of 3,3′-di-tert-butyl-5,5′-dimethoxy-[1,1′-biphenyl]-2,2′-diol and 40 mmol (4.8 g) of N,N-dimethylaminopyridine (DMAP) were dissolved in 900 ml of CH2Cl2. Subsequently, at room temperature, 400 mmol (88 g) of di-tert-butyl dicarbonate were dissolved in 280 ml of CH2Cl2, transferred to a 500 ml dropping funnel and added dropwise to the biphenol/DMAP solution at 32° C. within one hour. The solution was stirred at room temperature overnight. The next morning, the solvent was removed under reduced pressure. The slightly waxy, reddish solid was admixed with 800 ml of n-heptane and stirred overnight. This gave a white residue which was filtered off, washed twice with 50 ml of n-heptane and then dried. The target product was obtained as a white solid (161.6 g, 84%). 1H NMR (toluene-ds): 95% and further impurities.

##STR00029##

In a 250 ml Schlenk flask which had been repeatedly evacuated and filled with inert gas, 12 g (0.026 mol) of tert-butyl (3,3′-di-tert-butyl-2′-hydroxy-5,5′-dimethoxy-[1,1′-biphenyl]-2-yl)carbonate were dissolved by stirring in 120 ml of dried toluene and 12.8 ml (0.091 mol) of triethylamine.

In a second 500 ml Schlenk flask, 100 ml of dried toluene were first stirred together with 8.1 ml (0.091 mol) of phosphorus trichloride. Subsequently, the phosphorus trichloride-toluene solution was added dropwise to the previously prepared carbonate-amine-toluene solution at room temperature within 30 minutes. On completion of addition, the mixture was heated to 80° C. for 30 minutes and cooled to room temperature overnight.

The next morning, the mixture was filtered, the solids were washed with 50 ml of dried toluene, and the filtrate was concentrated to dryness. The target product was obtained as a solid (13.1 g, 89%). 31P NMR (202.4 MHz, toluene-ds): 203.2 and 203.3 ppm (100%).

##STR00030##

In a 1 l Schlenk flask which had been repeatedly evacuated and filled with inert gas, 24.7 g (0.044 mol) of tert-butyl (3,3′-di-tert-butyl-2′-((dichlorophosphino)oxy)-5,5′-dimethoxy-[1,1′-biphenyl]-2-yl)carbonate were dissolved in 400 ml of acetonitrile.

In a second Schlenk flask (1 l) which had been repeatedly evacuated and filled with inert gas, 10.8 g (0.044 mol) of 3,3′,5,5′-tetramethyl-(1,1′-biphenyl)-2,2′-diol were dissolved by stirring in 200 ml of acetonitrile and 13.1 ml (0.011 mol) of dried triethylamine. Subsequently, the chlorophosphite solution was slowly added dropwise to the biphenol-triethylamine solution and the mixture was stirred overnight.

The mixture was then filtered and the residue was washed twice with 15 ml of acetonitrile.

The filtrate was concentrated under reduced pressure until a solid precipitated out. The latter was filtered and dried. The target product was obtained as a white solid (28.5 g, 87%). 31P NMR (202.4 MHz, toluene-ds): 139.4 ppm (98.5%).

##STR00031##
Spectrometer: Bruker Avance 500 MHz FT spectrometer
Solvent: 1,1,2,2-tetrachloroethane (TCE)
Temperature: 353 K (80° C.)
Referencing: 1H NMR, 13C NMR: TMS=0

31P NMR: SR31P=SR1H*(BF31P/BF1H)=SR1H*0.404807

TABLE 1
Assignment of 1H chemical shifts of 1
δ/ppm Intensity Multiplicity Assignment
1.13 9H1 s 17d (tert-butyl)
1.20 9H s 20d (O-tert-butyl)
1.35 9H s 17c (tert-butyl)
2.02 3H broad s 7b (methyl)
2.28 3H s 8b (methyl)
2.31/2.32 6H broad s 7a (methyl)/8a
(methyl)
3.75 3H s 15c (O-methyl)
3.78 3H s 15d (O-methyl)
6.68 1H d 11d
6.83 1H d 11c
6.88 2H (1 + 1) m 5b, 13d
6.94 1H d 13c
6.96 1H s 5a
6.99 2H (1 + 1) s 3a + 3b
s: singlet
d: doublet
t: triplet
q: quartet
m: multiplet

TABLE 2
Assignment of 13C chemical shifts of 1
δ/ppm Intensity Group Assignment
16.35 1 CH3 7b
16.61 1 CH3 7a
20.66 1 CH3 8b
20.71 1 CH3 8a
27.38 3 CH3 20d
30.27 3 CH3 17d
30.41 3 CH3 17c
34.85 1 Cq 16c
35.02 1 Cq 16d
55.67 1 CH3 15d
55.79 1 CH3 15c
81.67 1 Cq 19d
113.86 1 CH 11c
114.01 1 CH 11d
114.14 1 CH 13c
114.60 1 CH 13d
127.65 1 CH 3b
127.88 1 CH 3a
128.72 1 Cq 10d
130.01 1 Cq 6b
130.77 1 Cq 6a
130.86 1 CH 5b
130.92 1 CH 5a
131.37 1 Cq 2b
131.50 1 Cq 2a
133.49 1 Cq 4b
133.65 1 Cq 4a
135.68 1 Cq 10c
142.09 1 Cq 9d
142.37 1 Cq 14d
143.60 1 Cq 9c
144.05 1 Cq 14c
145.88 1 Cq 1b
146.00 1 Cq 1a
151.27 1 Cq 18d
154.18 1 Cq 12d
157.19 1 Cq 12c

##STR00032##

In a 250 ml Schlenk flask which had been repeatedly evacuated and filled with inert gas, 9.1 g (0.021 mol) of 2-chloro-4,4,5,5-tetraphenyl-1,3,2-dioxaphospholane were dissolved in 75 ml of dried toluene.

In a second Schlenk flask (250 ml), 9.2 g (0.02 mol) of tert-butyl (3,3′-di-tert-butyl-2′-hydroxy-5,5′-dimethoxy-[1,1′-biphenyl]-2-yl)carbonate and 2.3 g (0.02 mol) of potassium tert-butoxide were dissolved in 75 ml of dried toluene while stirring.

Subsequently, the carbonate/potassium tert-butoxide/toluene mixture was slowly added dropwise at room temperature to the chlorophosphite solution, and the mixture was stirred at room temperature overnight.

Thereafter, the solvent was removed under reduced pressure. The resultant residue was stirred in 75 ml of dried acetonitrile for 5 hours. The solids were filtered, washed with dried acetonitrile and dried. The target product was obtained as a white solid (15.3 g, 90%). 31P NMR (202.4 MHz, toluene-ds): 147.0 ppm (99%).

##STR00033##
Referencing:

1H NMR: TMS=0 ppm, 31P NMR: SR31P=SR1H*(BF31P/BF1H)=SR1H*0.404807

TABLE 3
Assignment of the 13C chemical shifts of 2
δ [ppm] Intensity Group Assignment
157.31  1 × C Cq C9
155.29  1 × C Cq C16
152.22  1 × C Cq C24
143.68  1 × C Cq C13
143.66/143.54  2 × C Cq C7, C14
143.35  1 × C Cq C6
142.99/142.80  4 × C Cq C2
142.72/142.49
135.65  1 × C Cq C11
132.78  1 × C Cq C12
131.30/130.45  8 × C CH C4
129.66/129.04
127.40-126.90 12 × C CH C3, C5
115.17  1 × C CH C10
114.89  1 × C CH C8
114.83  1 × C CH C15
114.10  1 × C CH C17
95.64/94.85  2 × C Cq C1, C1′
81.32  1 × C Cq C25
55.08  1 × C CH3 C21
55.04  1 × C CH3 C18
35.25  1 × C Cq C19
35.09  1 × C Cq C22
30.77  3 × C CH3 C20
30.64  3 × C CH3 C23
27.56  3 × C CH3 C26

TABLE 4
Assignment of the 1H chemical shifts of 2
δ [ppm] Intensity Group Assignment
7.54 4H m H3, H4, H5
7.21 3H m H8, H10
7.09 5H m H15, H17
6.99-6.89 6H m
6.83 6H m
3.50 3H s H19
3.41 3H s H22
1.39 9H s H20
1.31 9H s H23
1.21 9H s H26

##STR00034##

In a 250 ml Schlenk flask which had been repeatedly evacuated and filled with inert gas, 10.5 g (0.019 mol) of tert-butyl (3,3′-di-tert-butyl-2′-((dichlorophosphino)oxy)-5,5′-dimethoxy-[1,1′-biphenyl]-2-yl)carbonate were dissolved in 50 ml of degassed acetonitrile while stirring.

In a second Schlenk flask (250 ml) which had been repeatedly evacuated and filled with inert gas, 3.6 g (0.019 mol) of 2,2′-biphenol were dissolved in 40 ml of degassed acetonitrile and 6.3 ml (0.045 mol) of dried triethylamine while stirring. Subsequently, the chlorophosphite mixture was slowly added dropwise at room temperature to the biphenol/triethylamine solution, and the mixture was stirred at room temperature overnight. The resultant solids were filtered and dried. The target product was obtained as a white solid (11.5 g, 90%). 31P NMR (202.4 MHz, toluene-ds): 146.2 ppm (100%).

##STR00035##

TABLE 5
Assignment of the 13C chemical shifts of 3
δ [ppm] Intensity Group Assignment
157.46 1 × C Cq C16
155.51 1 × C Cq C26
151.76 1 × C Cq C31
150.51/149.92 each 1 × C Cq C1 + C8
144.07 1 × C Cq C24
143.62 1 × C Cq C13
142.70 1 × C Cq C23
142.67 1 × C Cq C14
135.75 1 × C Cq C18
132.13/131.73 1 × C Cq C6 + C7
131.30 1 × C Cq C22
129.87/128.94 each 1 × C CH C5 + C12
128.98/128.91 each 1 × C CH C3 + C10
125.16/124.98 each 1 × C CH C4 + C11
123.54/122.40 each 1 × C CH C2 + C9
115.14 1 × C CH C25
114.93 1 × C CH C15
114.85 1 × C CH C27
114.72 1 × C CH C17
81.36 1 × C Cq C32
55.14 1 × C CH3 C28
55.10 1 × C CH3 C19
35.57 1 × C Cq C29
35.22 1 × C Cq C20
30.78 3 × C CH3 C30
30.62 3 × C CH3 C21
27.45 3 × C CH3 C33

TABLE 6
Assignment of the 1H chemical shifts of 3
δ [ppm] Intensity Group Assignment
7.26 1H d (J = 7.7 Hz) H2, H9, H3, H10
7.15-7.09 6H m H5, H12, H15, H25
7.02 1H t (J = 7.7 Hz)
6.95/6.91 2 × 1H 2 × t (J ~ 7.5 H4/H11
Hz)
6.93 1H d (J = 3 Hz) H17
6.87 1H d (J = 3 Hz) H27
3.48 3H s H19
3.42 3H s H29
1.50 9H s H20
1.35 9H s H21
1.16 9H s H33

##STR00036##

In a 250 ml Schlenk flask which had been repeatedly evacuated and filled with inert gas, 7.0 g (0.0125 mol) of tert-butyl (3,3′-di-tert-butyl-2′-((dichlorophosphino)oxy)-5,5′-dimethoxy-[1,1′-biphenyl]-2-yl)carbonate were dissolved in 100 ml of dried acetonitrile.

In a second Schlenk flask (100 ml) which had been repeatedly evacuated and filled with inert gas, 5.1 g (0.0125 mol) of 3,3′,5,5′-tetra-tert-butylbiphenol were dissolved in 60 ml of dried acetonitrile and 4.2 ml (0.03 mol) of dried triethylamine while stirring. Subsequently, the biphenol-triethylamine solution was slowly added dropwise at room temperature to the chlorophosphite solution and the mixture was stirred overnight. A portion of the solvent was removed under reduced pressure. The precipitated solids were filtered off and dried. The target product was obtained as a white solid (10.2 g, 91%). 31P NMR (202.4 MHz, toluene-d8): 142.7 ppm (100%).

##STR00037##

TABLE 7
Assignment of the chemical shifts of 4
Number δ-1H/ppm δ-13C/ppm
1 151.6
2 81.5
3 1.18 27.3
4 142.3
5 129.9
 6|18 6.76 114.7
6.67 114.1
 7|17 154.4
156.8
 8|16 6.93 113.5
6.88 115.4
9 143.6
10|19 3.78 55.4
3.74 55.7
11 35.0
12 1.39 30.6
21|29|31|39|41 1.03 31.2
1.24 31.0
1.29 31.4
1.34 31.5
1.39 30.7
1.48 31.3
13 136.4
14 142.1
15 140.1
20 34.6
22|32 146.0
146.9
24|34 7.06 126.6
7.30 123.8
25|35 145.1
146.3
26|36 7.08 126.3
7.42 124.1
28|38 35.1
35.2
30|40 34.6
35.4
23|33 135.5
132.6
27|37 140.0
141.9

##STR00038##

In a 250 ml Schlenk flask which had been repeatedly evacuated and filled with inert gas, 7 g (0.0125 mol) of tert-butyl (3,3′-di-tert-butyl-2′-((dichlorophosphino)oxy)-5,5′-dimethoxy-[1,1′-biphenyl]-2-yl)carbonate were dissolved in 100 ml of dried acetonitrile.

In a second Schlenk flask (100 ml) which had been repeatedly evacuated and filled with inert gas, 4.5 g (0.0125 mol) of 3,3-di-tert-butyl-5,5-dimethoxybiphenol were dissolved in 60 ml of dried acetonitrile and 4.2 ml (0.03 mol) of degassed triethylamine. Subsequently, the biphenol-triethylamine solution was slowly added dropwise at room temperature to the chlorophosphite solution and the mixture was stirred at room temperature overnight.

A portion of the solvent was removed under reduced pressure. The precipitated solids were filtered off and dried. The target product was obtained as a white solid (10.5 g, 96%). 31P NMR (202.4 MHz, toluene-ds): 140.9 (95.2%) and further impurities (further impurities=P—H compounds, oxide compounds, as yet incompletely converted chlorophosphite).

##STR00039##

In a 500 ml Schlenk flask which had been repeatedly evacuated and filled with inert gas, 6.8 g (0.012 mol) of tert-butyl (3,3′-di-tert-butyl-2′-((dichlorophosphino)oxy)-5,5′-dimethoxy-[1,1′-biphenyl]-2-yl)carbonate were dissolved in 100 ml of dried acetonitrile.

In a second Schlenk flask (250 ml) which had been repeatedly evacuated and filled with inert gas, 6 g (6 ml; 0.048 mol) of 2,4-dimethylphenol were dissolved in 100 ml of dried acetonitrile and 5 g (7 ml; 0.059 mol) of degassed triethylamine. Subsequently, the biphenol-triethylamine solution was slowly added dropwise at room temperature to the chlorophosphite solution and the mixture was stirred at room temperature overnight and cooled in an ice bath the next morning.

A portion of the solvent was removed under reduced pressure. This formed a slime-like solution which solidified after prolonged drying. The target product was obtained as a white solid (11.8 g, 62%). 31P NMR (202.4 MHz, toluene-ds): 139.1 (92.8%) and further impurities (further impurities=P—H compounds, oxide compounds, as yet incompletely converted chlorophosphite).

Procedure for the Catalysis Experiments

Experiment Description—General

In a 100 ml autoclave from Parr Instruments, various olefins were hydroformylated at various temperatures and synthesis gas pressure 20 or 50 bar (CO/H2=1:1 (% by vol.)). As precursor, 0.005 g of Rh(acac)(CO)2 was initially charged for a catalyst concentration of 40 ppm of Rh based on the overall reaction mixture, and correspondingly 0.0123 g of Rh(acac)(CO)2 for a concentration of 100 ppm of Rh. The solvent used was 40 to 46 g of toluene in each case. Ligand 1 was used in different molar excesses relative to rhodium. In addition, as GC standard, about 0.5 g of tetraisopropylbenzene (TIPB) was added. About 6 g of reactant were metered in after the reaction temperature envisaged had been attained.

During the reaction, the pressure was kept constant via metered addition of synthesis gas with a mass flow meter and pressure regulator. The stirrer speed was 1200 min−1. Samples were taken from the reaction mixture after 12 hours. The results of the experiments are summarized in Table 8 (yield=total yield of aldehyde and alcohol; S=selectivity for the linear product).

(acac=acetylacetonate)

TABLE 8
S
Starting p cRh P: Yield (n-aldehyde)
Entry material in [bar] in ppm Rh in % in %
1 cis-2- 20 40 4 58.0 45.3
butene
2 cis-2- 50 40 4 96.5 40.7
butene
3 1-butene 20 40 4 49.2 51.9
4 1-butene 50 40 2 97.4 46.8
5 1-butene 50 92 8 99.5 50.3
6 1-octene 50 40 9 97.1 43.2
Reaction conditions: ligand 1, reaction temperature 120° C.

Lines 1 and 2 list experiments on the rhodium-catalysed hydroformylation of the cis-2-butene reactant with ligand 1. At a synthesis gas pressure of 20 bar, in experiment 1, 58.0 mol % of pentanal is formed with a pentanal selectivity of 45.3%. The proportion of hydrogenation to the alkane is low at about 1.3% to 1.5%. The formation of pentanol is not observed. An increase in the synthesis gas pressure leads to a rise in the pentanal yield to 95.1 mol %, but the regioselectivity falls to about 40%.

Lines 3 to 5 list hydroformylations of 1-butene. At 20 bar (line 3), at a ligand excess of 4:1, a yield of about 49% and a selectivity for n-pentanal of about 52% are attained. At synthesis gas pressure 50 bar, a n-pentanal selectivity of 50% is obtained with virtually full conversion (lines 4 and 5). Alkane formation is low. In the experiment in line 4, the molar excess of ligand was reduced to about 2:1. The yield rises to 97.4%; the pentanal selectivity falls slightly to 46.8%. In line 5, the Rh concentration was increased to about 100 ppm and the ligand excess was increased to 8:1 relative to rhodium. The aldehyde yield rises to 99.5%; the regioselectivity likewise rises to 50.3%.

It is also possible to hydroformylate longer-chain olefins such as 1-octene with good n selectivity for the product (line 6).

Table 9 contains experiments on the hydroformylation of an n-octene mixture having about 2% 1-octene, 40% 2-octenes, 36% 3-octenes and 23% 4-octenes (yield=total yield of aldehyde and alcohol; S=selectivity for the linear n-pentanal product). In this case, the experiments were conducted both with the inventive ligand 1 and with the comparative TDTBPP ligand.

##STR00040##

TABLE 9
S (linear
T in cRh Yield product)
Entry [° C.] in ppm P:Rh in % in %
 1a 80 90 20 99.0 7.2
 2a 80 90 5 99.0 11.1
 3a 90 90 20 99.2 10.6
 4b 90 280 20 97.9 4.7
 5a 100 50 20 99.0 15.4
 6b 100 90 20 96.4 6.9
 7a 110 90 20 99.2 16.5
 8b 110 90 20 99.0 9.7
 9a 120 90 20 95.2 22.9
10b 120 90 20 99.0 14.4
11a 130 90 20 98.0 30.5
12b 130 76 20 98.8 23.9
13a 140 90 20 97.4 31.6
14b 140 56 20 98.0 23.9
15a 120 90 4 98.9 28.8
16a 120 40 9.5 98.6 29.1
17a 120 40 20 99.1 28.2
Reaction conditions: 50 bar of synthesis gas (CO/H2); substrate: n-octenes; a): ligand 1; b): ligand TDTBPP.

Entries 1 to 14 each show results of experiments at a constant temperature in the range from 80° C. to 140° C., in each case for the inventive ligand 1 and for the comparative ligand (TDTBPP). As is clearly apparent, the inventive ligand 1 in all cases shows a distinctly higher n selectivity for the desired product combined with very good overall yields. The formation of alkanes and alcohols is insignificant. If entries 13 and 14 are compared, ligand 1 has nearly an 8% increase in selectivity compared to the commercially available comparative ligand. Entries 15 to 17 show the use of ligand 1 with different molar excesses relative to rhodium. In all cases, it was possible to achieve very good n selectivities.

Table 10 gives the results for the hydroformylation of di-n-butene. Di-n-butene is a mixture of isomers of n-octenes (about 16%), 3-methylheptenes (about 65%) and 3,4-dimethylhexenes (about 19%) (yield=total yield of aldehyde and alcohol; S=selectivity for the linear product).

TABLE 10
T p cRh Yield S (nl)*
Entry in [° C.] in [bar] in ppm P:Rh in % in %
1 120 50 40 10 85.1 30.8
2 120 50 90 7 89.8 28.3
3 120 50 90 7 91.5 30.9
4 120 50 100 5 93.0 36.5
5 120 50 75 20 94.6 29.8
6 130 50 75 20 95.3 32.7
7 110 50 75 20 91.9 24.0
8 120 40 75 20 94.8 29.0
Reaction conditions: ligand 1; substrate: di-n-butene
*Proportion of the aldehydes formed through terminal hydroformylation (essentially nonanal, 4-methyloctanal, 3-ethylheptanal, 6-methyloctanal, 4,5-dimethylheptanal and 3-ethyl-4-methylhexanal)

The above Table 10 contains experimental results for the rhodium-catalysed hydroformylation of di-n-butene with ligand 1. Entries 1 to 5 were conducted at 120° C. and 50 bar, and entry 8 at 40 bar. Entries 2 and 3 are a double determination with a ligand excess of 7 relative to rhodium and a rhodium concentration based on the overall reaction mixture of 80 ppm; entry 1 was performed at an excess of about 10:1 and an Rh concentration of 40 ppm. Entry 4 describes a reduction in the excess to 5:1 compared to entries 2 and 3. Entries 5 to 8 are experiments with a high ligand excess of about 20:1. Entries 5 to 7 were conducted at different temperatures. Entry 8 differs from entry 5 by the pressure. Analogously to the experiments with the n-octene mixture, high n selectivities between 28 and 36 mol % are found in all of experiments 1 to 6 and 8. At lower temperature (entry 7), the n selectivity is reduced to about 24%. n-Octenes are converted virtually quantitatively within the experimental duration of 12 hours; the conversion of the 3-methylheptenes is >96%. The 3,4-dimethylhexenes are converted to an extent of 73%-86%. It was thus possible to show with the aid of the above examples that the novel catalyst system is also suitable for hydroformylation of technical olefin mixtures containing mainly branched olefins containing internal double bonds, and a high proportion of desired terminally hydroformylated products can be obtained.

Table 11 gives the results for the hydroformylation of n-octenes with ligand 3 (yield=total yield of aldehyde and alcohol; S=selectivity for the linear product).

TABLE 11
T Yield S (linear product)
Entry in [° C.] in % in %
1 80 30.0 8.6
2 90 85.9 4.9
3 100 91.3 5.9
4 110 98.5 8.3
5 120 99.0 11.9
Reaction conditions: ligand 3; 50 bar of synthesis gas; substrate: n-octcnes; cRh = 90 ppm; L/Rh = 20.

The above table contains a compilation of the experimental data for the hydroformylation of n-octenes with ligand 3 in the form of a temperature series from 80° C. to 120° C. at synthesis gas pressure 50 bar, an Rh concentration of about 100 ppm and a ligand excess of about 20:1. The n-nonanal selectivities in this series of experiments are low at 4.9 to 11.9 mol %, but the aldehyde yields at higher temperatures are virtually quantitative and very good. Alkane formation is low at <1%; hydrogenation to alcohols is not observed.

Table 12 gives the results for the hydroformylation of di-n-butene. Di-n-butene is a mixture of isomers of n-octenes (about 16%), 3-methylheptenes (about 65%) and 3,4-dimethylhexenes (about 19%) (yield=total yield of aldehyde and alcohol; S=selectivity for the linear product).

TABLE 12
T p cRh Yield
Entry Ligand in [° C.] in [bar] in ppm P:Rh in %
1 4 140 50 100 20:1 38
2 3 140 50 100 10:1 74
3 5 120 50 100 20:1 85
4 5 130 50 100 20:1 86
5 5 140 50 100 20:1 96
6 5 140 50 100 15:1 97
7 5 140 50 100  5:1 97
Reaction conditions: ligand 1; substrate: di-n-butene
*Proportion of the aldehydes formed through terminal hydroformylation (essentially nonanal, 4-methyloctanal, 3-ethylheptanal, 6-methyloctanal, 4,5-dimethylheptanal and 3-ethyl-4-methylhexanal)

The above Table 12 contains experimental results for the rhodium-catalysed hydroformylation of di-n-butene with ligands 3, 4 and 5. While ligand 4 (entry 1) gives a moderate overall yield of aldehydes and alcohols, ligands 3 and 5 are notable for very good yields. Especially ligand 5 shows virtually quantitative yields at elevated temperature (140° C.) (entries 5 to 7).

It was thus possible to show with the aid of the above examples that the novel catalyst system is also suitable for hydroformylation of technical olefin mixtures containing mainly branched olefins containing internal double bonds, and a high proportion of desired hydroformylated products can be obtained.

The inventive monophosphite ligands have a very good n selectivity in relation to the hydroformylation. Selectivity for the desired linear aldehydes is much greater here than, for example, in the case of the commercially available TDTBPP ligand. The stated objects are therefore achieved by these novel inventive ligands.

German patent application 102014209532.8 filed May 20, 2014, is incorporated herein by reference.

Numerous modifications and variations on the present invention are possible in light of the above teachings. It is therefore to be understood that within the scope of the appended claims, the invention may be practiced otherwise than as specifically described herein.

Dyballa, Katrin Marie, Franke, Robert, Fridag, Dirk, Geilen, Frank, Hess, Dieter

Patent Priority Assignee Title
11185852, May 29 2017 LG Chem, Ltd Catalyst composition for hydroformylation and method of preparing aldehyde using the same
9605010, Apr 29 2015 EVONIK OXENO GMBH & CO KG Monophosphite compounds having a methyl group
9605011, Apr 29 2015 Evonik Operations GmbH Monophosphite compounds having an ether group
9676805, Jan 31 2014 EVONIK OXENO GMBH & CO KG Purifying organophosphorus compounds contaminated with chlorine
Patent Priority Assignee Title
20110230620,
20140309423,
DE102011085883,
EP614870,
WO2010057099,
/////////
Executed onAssignorAssigneeConveyanceFrameReelDoc
May 18 2015EVONIK INDUSTRIES AG(assignment on the face of the patent)
Jul 16 2015GEILEN, FRANKEVONIK INDUSTRIES AGASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS 0361960221 pdf
Jul 20 2015DYBALLA, KATRIN MARIEEVONIK INDUSTRIES AGASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS 0361960221 pdf
Jul 20 2015FRANKE, ROBERTEVONIK INDUSTRIES AGASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS 0361960221 pdf
Jul 20 2015HESS, DIETEREVONIK INDUSTRIES AGASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS 0361960221 pdf
Jul 20 2015FRIDAG, DIRKEVONIK INDUSTRIES AGASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS 0361960221 pdf
Nov 19 2015EVONIK INDUSTRIES AGEvonik Degussa GmbHASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS 0371740982 pdf
Oct 02 2019Evonik Degussa GmbHEvonik Operations GmbHCHANGE OF NAME SEE DOCUMENT FOR DETAILS 0517650166 pdf
Oct 12 2023Evonik Operations GmbHEVONIK OXENO GMBH & CO KGCONFIRMATORY ASSIGNMENT0654630144 pdf
Date Maintenance Fee Events
Apr 25 2016ASPN: Payor Number Assigned.
Jun 18 2019M1551: Payment of Maintenance Fee, 4th Year, Large Entity.
Aug 21 2023REM: Maintenance Fee Reminder Mailed.
Feb 05 2024EXP: Patent Expired for Failure to Pay Maintenance Fees.


Date Maintenance Schedule
Dec 29 20184 years fee payment window open
Jun 29 20196 months grace period start (w surcharge)
Dec 29 2019patent expiry (for year 4)
Dec 29 20212 years to revive unintentionally abandoned end. (for year 4)
Dec 29 20228 years fee payment window open
Jun 29 20236 months grace period start (w surcharge)
Dec 29 2023patent expiry (for year 8)
Dec 29 20252 years to revive unintentionally abandoned end. (for year 8)
Dec 29 202612 years fee payment window open
Jun 29 20276 months grace period start (w surcharge)
Dec 29 2027patent expiry (for year 12)
Dec 29 20292 years to revive unintentionally abandoned end. (for year 12)